Prostaglandin E1 receptor

Class

PGE1 vasodilator (continuous IV infusion, advanced-HF application)

Prostaglandin E1 (PGE1) is a naturally occurring lipid signaling molecule that acts on a family of related G-protein-coupled receptors on the surface of vascular smooth muscle and platelets, collectively referred to here as the PGE1 (EP) receptors. Binding of PGE1 or its synthetic analog to these receptors triggers relaxation of smooth muscle in blood vessel walls, producing vasodilation, and also reduces platelet aggregation. In cardiovascular disease, and particularly in advanced heart failure, the heart struggles to pump against the resistance of a constricted vascular system. Reducing that resistance—known as afterload—and easing the pressure the heart must generate can improve blood flow to organs without requiring the heart muscle itself to work harder. This is the general rationale for using a vasodilator such as a PGE1 analog delivered by continuous intravenous infusion in this setting: it lowers vascular tone systemically, potentially improving cardiac output and organ perfusion in patients whose hearts have limited reserve. The same underlying biology—smooth muscle relaxation through this receptor pathway—is exploited in other clinical contexts as well, since vasodilation is broadly useful wherever blood flow is inadequate. The approach carries an inherent trade-off: because the vasodilation is systemic rather than confined to a single vascular bed, blood pressure can fall more than desired, which is a central consideration whenever this class of agent is used.